Royalty Pharma plc
NasdaqGS-RPRX
Company Overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Name
Royalty Pharma plc
CEO
Mr. Pablo Gerardo Legorreta
Website
www.royaltypharma.com
Sector
Pharmaceuticals
Year Founded
1996
Profile
Market Cap
$12.42B
EV
$21.5B
Shares Out
448.13M
Revenue
$2,237.63M
Employees
—
Margins
Gross
55.46%
EBITDA
63.61%
Operating
42.91%
Pre-Tax
46.02%
Net
30.09%
FCF
119.28%
Returns (5Yr Avg)
ROA
4.6%
ROTA
8.05%
ROE
8.03%
ROCE
8.72%
ROIC
—
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$44.75
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$1,803.14M
Net Debt
$5,798.88M
Debt/Equity
0.78
EBIT/Interest
5.15
Growth (CAGR)
Rev 3Yr
-0.01%
Rev 5Yr
5.58%
Rev 10Yr
—
Dil EPS 3Yr
-15.33%
Dil EPS 5Yr
-41.67%
Dil EPS 10Yr
—
Rev Fwd 2Yr
9.8%
EBITDA Fwd 2Yr
-0.37%
EPS Fwd 2Yr
0.09%
EPS LT Growth Est
4.2%
Dividends
Yield
—
Payout
54.63%
DPS
$0.82
DPS Growth 3Yr
8.61%
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
10.01%